Banden met industrie

Op de site van de NVPC wordt gerefereerd aan een aantal onderzoeken. Die hebben we onder de loep genomen en het blijkt dat een aantal van de wetenschappers banden hebben/hadden met de industrie en daardoor niet objectief. Het SVS beseft dat onderzoek van de industrie natuurlijk nodig is, maar bij zo'n controversieel product waar zoveel tegenstrijdigheid heerst, zetten wij onze vraagtekens bij een aantal onderzoeken. Om een voorbeeld te geven in 2012 werd maar liefst tussen $240.001,00 en $250.000,00 betaald aan Scott Spear, voor zijn nevenwerkzaamheden , náást zijn normale werk als plastisch chirurg, door Allergan, (zie onderstaande verwijzing).

Namen van onderzoekers die betaald werden door de industrie: >> Bij de zoekfunctie kunt u zelf naam arts en/of fabrikanten intypen

Een paar voorbeelden:

Dr. W.H Beekman . >>Leo Peter van der Weij >>

Gedragscodes voor financiële relaties in de zorg >>

Transparantieregister >>

Unites Scientists

In de database van de United Scientists – een site over commercialisering van de wetenschap - 'About integrity in Science' vonden we een aantal wetenschappers die zich hebben bezig gehouden met onderzoek naar siliconen borstimplantaten, die tegelijk financiële banden hadden met de industrie.

Onderstaande informatie doet sterk vermoeden dat de goedkeuring van de borstimplantaten in de VS in 1992, gebaseerd is op beïnvloede onderzoekresultaten.

Er zijn twee grote onderzoeken, waarnaar veel verwezen werd door overheden, die aantonen dat siliconen borstimplantaten geen auto-immuunziekten kunnen veroorzaken. Hierdoor mochten de implantaten (onterecht) op de markt blijven.

1. ‘Risk of connective tissue disease and related disorders among women with breast implants: a nation-wide retrospective cohort study in Sweden’. >>

Conclusie: This large nationwide cohort study shows no evidence of association between breast implants and connective tissue disease.

Onderzoekers van dit onderzoek, die voorkomen in de database van ‘Integrity in Science’ :

McLaughlin JK, Blot WJ, Boice JD Jr, Adami HO, Karolinska Institute.

2. ‘Breast implants and risk of neurologic disease: a population-based cohort study in Sweden’. >>

Conclusie: Our results provide no support for the conjecture that breast implants cause neurologic disease.


Integrety in Science

Onderzoekers van dit onderzoek, die voorkomen in de database: ‘Integrity in Science’,

McLaughlin JK, Blot WJ, Adami HO.

Joseph K. McLaughlin, Ph.D , President of the for-profit International Epidemiology Institute, which has received funding from the Dow Corning Corp. and 3M Company. (Annals of Plastic Surgery. 2007 November; 59:569-580.) http://www.iei.ws/; accessed 1/09/08) Heeft meegewerkt aan 73 wetenschappelijke publicaties over borstimplantaten

William J. Blot. Ph.D (zie hiernaast: Vanderbilt University)

John D. Boice, Jr., Sc.D., Professor of Medicine, Department of Medicine at the Vanderbilt University Medical Center, Nashville, TN. Scientific Director of the for-profit International Epidemiology Institute. (telephone interview: 11/23/04 and http://www.ieiltd.com/bios.htm; accessed 11/09/04

Hans-Olov Adami, Professor of cancer epidemiology, Karolinska Institute, Sweden (zie hiernaast). Hired by the product-defense firm Exponent Inc. to conduct research on dioxins and present findings at the 2001 conference on dioxins in Korea. ("Secret Ties to Industry and Conflicting Interests in Cancer Research," Am J Ind Med. 50:227-233 [2007]) Confirms that 1995 studies (Cancer Causes Control 6:551-566 and Crit Rev Toxicol 25:463-531), which called link between organochlorines, notably DDT, and hormone-dependent cancers in women "highly unlikely," were supported by industry. (Letter to the Editor, Am J Ind Med. 50:237 [2007])


Meer aanwijzingen

Secret Ties to industry and conflicting interests in cance research >>

A number of research projects have taken place at the Karolinska Institute, Stockholm with participation of Boice and McLaughlin, with a funding model through IEI. One of he studies was published in British Medical Journal [Nyre´n et al., 1998] with Adami as a co-author. A cohort of Swedish women with breast implants was studied with regard to connective tissue disease.No risk was found. Thanks to strict rules of stating conflicts of interest in the British Medical Journal it can be seen that the project was initiated by IEI, and that the funding from IEI was on behalf of Dow Corning,producer of silicon breast implants.

Karolinska Institute

  1. Hans-Olov Adami, Professor of cancer epidemiology, Karolinska Institute, Sweden. Hired by the product-defense firm Exponent Inc. to conduct research on dioxins and present findings at the 2001 conference on dioxins in Korea. ("Secret Ties to Industry and Conflicting Interests in Cancer Research," Am J Ind Med. 50:227-233 [2007]) Confirms that 1995 studies (Cancer Causes Control 6:551-566 and Crit Rev Toxicol 25:463-531), which called link between organochlorines, notably DDT, and hormone-dependent cancers in women "highly unlikely," were supported by industry. (Letter to the Editor, Am J Ind Med. 50:237 [2007]
  2. Margarita Diez, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. Research on decreased protein binding in discrete hippocampal regions of prion infected mice was supported in part by an unrestricted Bristol-Myers Squibb Neuroscience Grant. (Soc. Neurosci. Abstr., Vol. 27, Program No. 528.2, 2001)
  3. Tomas Hökfelt, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. Research on decreased protein binding in discrete hippocampal regions of prion infected mice was supported in part by an unrestricted Bristol-Myers Squibb neuroscience grant. (Soc. Neurosci. Abstr., Vol. 27, Program No. 528.2, 2001)
  4. Dimitrios Trichopoulos, M.D., Professor of Cancer Prevention, Department of Epidemiology, Harvard School of Public Health, Boston, and Adjunct Professor of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden. Serves as an advisor to the for-profit International Epidemiology Institute. (telephone interview: 11/23/04 and http://www.ieiltd.com/accessed 11/09/04) Hired by the product-defense firm Exponent Inc. to conduct research on dioxins and present findings at the 2001 conference on dioxins in Korea. ("Secret Ties to Industry and Conflicting Interests in Cancer Research," published online ahead of print 11/3/06 in Am J Ind Med.) Wrote a paper for Monsanto in fall, 1996, concerning John Olney’s paper on aspartame (on file w/ CSPI) Received consulting fees from Coca-Cola and NutraSweet. (N Engl J Med. 2003;348:1623-4.) Member of the advisory committee for the General Motors Cancer Research Foundation (GMCRF).
  5. accessed 6/27/03)
  6. Ronald van Vollenhoven, M.D., Ph.D., Associate Professor of Rheumatology, Karolinska Institute, Stockholm, Sweden. Received research support from Abbott Pharmaceuticals, Bristol-Myers Squibb, Centocor, Roche, Schering-Plough, and Wyeth;consultant to Abbott Pharmaceuticals, Bristol-Myers Squibb, Centocor, Roche, Schering-Plough, and Wyeth; speakers’ bureaus for Abbott Pharmaceuticals, Roche, Schering-Plough, and Wyeth. accessed 7/26/05) inloggen

Vanderbilt University

  1. Mark I. Appelbaum, Ph.D., Department of Psychology and Human Development, Vanderbilt University. Study on sucrose and behavior supported in part by the Nutrition Foundation - ILSI. (New Engl. J. Med. 1994;330:301-7).
  2. William J. Blot, Ph.D., Professor of Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. Chief Executive Officer of the for-profit International Epidemiology Institute. (telephone interview: 11/23/04 and accessed 11/09/04)
  3. John D. Boice, Jr., Sc.D., Professor of Medicine, Department of Medicine at the Vanderbilt University Medical Center, Nashville, TN. Scientific Director of the for-profit International Epidemiology Institute. (telephone interview: 11/23/04 and accessed 11/09/04)
  4. Stanley Cohen, Ph.D., Professor of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN. Member of the scientific and medical advisory boards for Cephalon.accessed 7/30/03)
  5. Doyle G. Graham, M.D., Ph.D., Vanderbilt University. Member of the Science Advisory Committee, Chemical Industry Institute of Toxicology, 1997-99. (CIIT 1997 annual report, memo received 12/16/98)
  6. Kathy Jabs, M.D., Director of Pediatric Nephrology, Vanderbilt Children's Hospital, Associate Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN. Received research funds, grants and/or contracts from King Pharmaceuticals and Watson Pharmaceuticals. accessed 1/23/07)
  7. Loren Lipworth, ScD., Assistant Professor of Preventive Medicine, Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt University, Nashville, TN. Member of the for-profit International Epidemiology Institute, which has received funding from the Dow Corning Corporation and 3 M Company. (Annals of Plastic Surgery. 2007 November; 59:569-580.) accessed 1/09/08) Deze wetenschapper heeft meegewerkt aan 35 wetenschappelijke publicaties over borstimplantaten
  8. James E. Lloyd, M.D., F.C.C.P., Professor of Medicine, Vanderbilt University Medical Center, Nashville, TN. Has relationships (undefined in the disclosure) with GlaxoSmithKline, United Therapeutics, Actelion, ICOS/Texas Biotechnology, Westat, PRA International, Pfizer, and Exhale Therapeutics. (Chest 2004;126:1)
  9. Joseph K. McLaughlin, Ph.D., President of the for-profit International Epidemiology Institute, which has received funding from the Dow Corning Corp. and 3M Company. (Annals of Plastic Surgery. 2007 November; 59:569-580.) accessed 1/09/08)
  10. Herbert Meltzer, M.D., Professor of Psychiatry & Pharmacology and Director of the Division of Psychopharmacology, Vanderbilt University Medical Center, Nashville, TN. Consultant, speakers bureau, and honoraria/grant/research support from Eli Lilly, Pfizer, GlaxoSmithKline, Janssen, and AstraZeneca. (Preliminary Report of the Task Force on SSRIs and Suicidal Behavior in Youth, American College of Neuropsychopharmacology, January 21, 2004, p.16; on file with CSPI)
  11. Douglas F. Milam, M.D., Associate Professor, Urologic Surgery Department, Vanderbilt University. Study on effectiveness of drugs used to treat benign prostatic hyperplasia partially funded by Merck and Pfizer. Consultant to and received funding from Pfizer. (New Engl J Med 2003;349:2387-98)
  12. Wayne A. Ray, Ph.D., Professor of Preventative Medicine, Director of the Division of Pharmacoepidemiology, Vanderbilt University School of Medicine, Nashville, TN. Served as a consultant to Pfizer and to plaintiffs' attorneys regarding rofecoxib. (Lancet. 2005 Feb 5;365(9458):475-81.) Consultant to Pfizer and Bristol-Myers Squibb; research funding from Pfizer; expert testimony for litigation involving cerivastatin, fenfluramine derivatives, and rofecoxib. (N Engl J Med. 2004;351:1089-96.) Research support from Pfizer, Inc.; consultant for Pfizer, Inc accessed 7/8/05) inloggen
  13. John Sergent, M.D., professor of medicine, Vanderbilt University. Consultant/expert witness for Baxter Healthcare, Dow Corning, 3M, Bristol-Myers Squibb. (Brill’s Content, 10/98, p.108)
  14. David Shaffer, M.D., Professor of Surgery, School of Medicine, Vanderbilt University, Nashville, TN. Principal Investigator for 2003-04 study funded by Novartis on the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and corticosteroids versus Mycophenolate Mofetil combined with full dose Neoral and corticosteroids in de novo adult renal transplant recipients. Principal Investigator in 2002 study funded by Fujisawa Healthcare on corticosteroid therapy in renal transplant recipients. Principal investigator in 2002-3 study funded by Sangstat on calcineurin inhibitor avoidance. Co-Investigator in 2000-1 study funded by Wyeth-Ayerst Research Institute on the evaluation of graft function in de novo renal allograft recipients treated with either a “reduced dose” or a “standard dose” of cyclosporine in combination with Rapamune (sirolimus) and corticosteroids. Co-Investigator in 2000-1 study funded by Wyeth-Ayerst Research Institute of the effects of single ascending doses of humanized anti B7.1 (h1F1) and B7.2 (h1D3) in de novo renal transplant patients. Principal Investigator in 1999-2000 study funded by Wyeth-Ayerst Research on tolerance induction in a primate model using co-stimulation blockade based treatment. (Resume on file with CSPI)
  15. Joseph A. Smith, M.D., Surgical Oncologist, Vanderbilt University Medical Center. Study on effectiveness of drugs used to treat benign prostatic hyperplasia partially funded by Merck and Pfizer. (New Engl J Med 2003;349:2387-98)
  16. Michael F. Vaezi, M.D., Professor of Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN. Speaker's bureau of AstraZeneca; consultant for AstraZeneca, Santarus, and Restech; receives grant support from TAP Pharmaceutical Products, AstraZeneca, and Restech. accessed 11/26/08) >>
  17. Mark Wolraich, M.D., Department of Pediatrics, Vanderbilt University. Study on sucrose and behavior supported in part by the Nutrition Foundation - ILSI. (New Engl. J. Med. 1994;330:301-7) When at Iowa City Department of Pediatrics, University Hospital School, the Sugar Associates (sugar industry) funded study on sucrose and behavior. (J. Pediatrics. 1985;106:675)
  18. Alastair J. Wood, M.D., Assistant Vice Chancellor, Professor of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN. Served on the January 2006 FDA nonprescription drugs advisory committee evaluating GlaxoSmithKline’s OTC application of Orlistat and was given a waiver for receiving less than $10,001 in consulting fees from a Glaxo competitor on an unrelated matter. http://www. fda.gov/ohrms/dockets/ac /06/waivers/2006-4201w1-index.html; accessed 1/30/06) Co-inventor of 12/11/01 U.S. patent 6,329,153 “Method for evaluating immunosuppressive” assigned to Vanderbilt University. Served on Board of Directors of Antigenics. (Antigenics Reports Third Quarter 2004 Financial Results and Recent Highlights, Business Wire, 10/19/04) Co-authored “The effect of common polymorphisms of the ß2-adrenergic receptor on agonist-mediated vascular desensitization” sponsored in part by Merck. (N Engl J Med. 2001;345:1030-5.) Co-authored an article on HIV funded in part by Lilly Research Laboratories. (Drug Metab Dispos. 2000;28:655-60.)